The impact of Alzheimer's disease medication on muscle relaxants.
Russell
W J
WJ
D000544:Alzheimer Disease / Q000188:drug therapy*; D000732:Androstanols / Q000009:adverse effects / Q000037:antagonists & inhibitors; D002800:Cholinesterase Inhibitors / Q000009:adverse effects*; D000077265:Donepezil; D004347:Drug Interactions; D006801:Humans; D007189:Indans / Q000009:adverse effects*; D009467:Neuromuscular Depolarizing Agents / Q000009:adverse effects*; D003473:Neuromuscular Nondepolarizing Agents / Q000009:adverse effects / Q000037:antagonists & inhibitors; D010880:Piperidines / Q000009:adverse effects*; D000077123:Rocuronium; D013390:Succinylcholine / Q000009:adverse effects*; D000077122:Sugammadex; D047408:gamma-Cyclodextrins / Q000494:pharmacology
D000732:Androstanols; D002800:Cholinesterase Inhibitors; D007189:Indans; D009467:Neuromuscular Depolarizing Agents; D003473:Neuromuscular Nondepolarizing Agents; D010880:Piperidines; D047408:gamma-Cyclodextrins; D000077122:Sugammadex; D000077265:Donepezil; D013390:Succinylcholine; D000077123:Rocuronium